Literature DB >> 27583590

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.

Tim R Cressey1, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham, Jennifer R King, Paula Britto, Vincent J Carey, Edward P Acosta, Ram Yogev.   

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27583590      PMCID： PMC5106325          DOI： 10.1097/INF.0000000000001320

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  10 in total

1.  Guidelines for the use of antiretroviral agents in pediatric HIV infection, January 7, 2000.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Nov-Dec

2.  Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

Authors:  Jennifer J Kiser; Richard M Rutstein; Pearl Samson; Bobbie Graham; Grace Aldrovandi; Lynne M Mofenson; Elizabeth Smith; Steven Schnittman; Terry Fenton; Richard C Brundage; Courtney V Fletcher
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

Review 3.  Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Authors:  Clotilde Le Tiec; Aurélie Barrail; Cécile Goujard; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.

Authors:  Sylvain Goutelle; Thomas Baudry; Marie-Claude Gagnieu; André Boibieux; Jean-Michel Livrozet; Dominique Peyramond; Christian Chidiac; Michel Tod; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 5.  Atazanavir: in pediatric patients with HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

6.  Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Authors:  Richard M Rutstein; Pearl Samson; Terry Fenton; Courtney V Fletcher; Jennifer J Kiser; Lynne M Mofenson; Elizabeth Smith; Bobbie Graham; Marina Mathew; Grace Aldrovani
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

7.  Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.

Authors:  Stefano Bonora; Daniel Gonzalez de Requena; Antonio D'Avolio; Andrea Calcagno; Mariacristina Tettoni; Marco Siccardi; Lorena Baietto; Marco Simiele; Laura Trentini; Giovanni Di Perri
Journal:  Antivir Ther       Date:  2011

8.  Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Authors:  C Cohen; L Nieto-Cisneros; C Zala; W J Fessel; J Gonzalez-Garcia; A Gladysz; R McGovern; E Adler; C McLaren
Journal:  Curr Med Res Opin       Date:  2005-10       Impact factor: 2.580

9.  Use of therapeutic drug monitoring in HIV disease.

Authors:  Matthijs van Luin; Paul Fm Kuks; David M Burger
Journal:  Curr Opin HIV AIDS       Date:  2008-05       Impact factor: 4.283

10.  Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.

Authors:  Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Sara Gibbons; Mauro Sciandra; Daniela Colucci; Stefano Bonora; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079
  10 in total
  1 in total

Review 1.  Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.

Authors:  Hylke Waalewijn; Anna Turkova; Natella Rakhmanina; Tim R Cressey; Martina Penazzato; Angela Colbers; David M Burger
Journal:  Ther Drug Monit       Date:  2019-08       Impact factor: 3.681
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.